The "King Kong" of weight loss medications, Mounjaro (tirzepatide), is a dual GIP and GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes mellitus and for weight loss. As with any medication affecting pancreatic function, questions have emerged regarding potential links between Mounjaro and pancreatic cancer. Current evidence from clinical trials and regulatory reviews does not establish a causal relationship between tirzepatide and pancreatic malignancy. L

At the moment, there is no generic version of Mounjaro available. The medication is still under patent protection, meaning only Eli Lilly can produce tirzepatide until that period ends. Generic versions may become available in future years, once regulatory timelines and patent conditions allow. Understanding what “generic” means A generic medicine is an equivalent version of a branded drug that becomes available once patent and exclusivity rights expire. It must contain the s

Mounjaro was developed by the pharmaceutical company Eli Lilly and first approved for medical use in 2022. It’s based on years of research into dual hormone therapies that target both GIP and GLP-1 pathways. Its effectiveness has since been demonstrated in large international trials, helping establish it as a new generation of treatment for type 2 diabetes and weight management. How Mounjaro began The story of Mounjaro started in the early 2010s, when researchers explored way

Evidence suggests Mounjaro can support sustained weight loss when used alongside lasting lifestyle changes. Long-term studies show participants maintained significant reductions in both weight and blood sugar over a year or more of treatment. Continued success depends on consistency, as stopping the medication may lead to weight regain if healthy habits aren’t maintained. What the long-term trials show The main long-term evidence comes from the SURMOUNT-1 and SURMOUNT-4 studi

Mounjaro targets two key hormone receptors in the body — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). These hormones help regulate blood sugar, appetite, and energy use. By acting on both, Mounjaro improves how your body handles glucose while also curbing hunger, helping support steady, sustainable weight loss. How the GIP and GLP-1 hormones work Both GIP and GLP-1 are naturally released from the gut after eating. They signal the pan

Imagine the possibilities of a single weekly injection transforming the battle against obesity. That's precisely what tirzepatide,...